Clinical Trial Update: Evaluating the Safety and Efficacy of Topical Sirolimus 0.2% to Treat Acanthosis Nigricans [Phase 2]

View source ↗

Summary

A completed Phase 2 trial investigates the safety and efficacy of topical sirolimus 0.2% for treating Acanthosis Nigricans.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acanthosis Nigricans

Drugs mentioned

• Topical Sirolimus 0.2% (sirolimus)

Snippet

Sponsor: Narrows Institute for Biomedical Research | Conditions: Acanthosis Nigricans | Phase 2 | Status: COMPLETED